{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:08:41Z","timestamp":1793646521074,"version":"4.5.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016872","name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1745302"],"award-info":[{"award-number":["1745302"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006598","name":"Department of Mechanical Engineering, Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006598","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006919","name":"Massachusetts Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006919","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.medj.2024.03.020","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T10:38:58Z","timestamp":1713955138000},"page":"780-796.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Closed-loop automated drug infusion regulator: A clinically translatable, closed-loop drug delivery system for personalized drug dosing"],"prefix":"10.1016","volume":"5","author":[{"given":"Louis B.","family":"DeRidder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmeline","family":"MacPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niora","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline N.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameya R.","family":"Kirtane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiam","family":"Madani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes L.P.","family":"Kuosmanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Zecharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Colangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hen-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makaya","family":"Chilekwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil B.","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriya S.","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Wolpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Trumper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Quast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Rubinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7851-4077","authenticated-orcid":false,"given":"Giovanni","family":"Traverso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.03.020_bib1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","article-title":"Therapeutic drug monitoring of 5-fluorouracil","volume":"78","author":"Lee","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.medj.2024.03.020_bib2","article-title":"Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer","author":"Cespedes Feliciano","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2024.03.020_bib3","first-page":"119","article-title":"Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens","volume":"13","author":"Kline","year":"2014","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.medj.2024.03.020_bib4","doi-asserted-by":"crossref","first-page":"e19562","DOI":"10.1200\/jco.2011.29.15_suppl.e19562","article-title":"Point-of-care (POC) diagnostic assay for 5-fluorouracil (5-FU) quantitation to enable dose adjustment and detect dihydropyrimidine dehydrogenase (DPD) deficiency","volume":"29","author":"White","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.03.020_bib5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","article-title":"Clinical Calorimetry: Tenth Paper. A formula to estimate the approximate surface area if height and weight be known","volume":"XVII","author":"Du BOIS","year":"1916","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.medj.2024.03.020_bib6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jconrel.2022.10.043","article-title":"The past, present, and future of chemotherapy with a focus on individualization of drug dosing","volume":"352","author":"DeRidder","year":"2022","journal-title":"J.\u00a0Controlled Release"},{"key":"10.1016\/j.medj.2024.03.020_bib7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.1994.123","article-title":"Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: Relationship with mucosal toxicity in patients with cancer","volume":"56","author":"Metzger","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.medj.2024.03.020_bib8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified Calculation of\u00a0Body-Surface Area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.03.020_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/cts.12726","article-title":"Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer Therapy","volume":"13","author":"Reyner","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.medj.2024.03.020_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.tips.2019.04.014","article-title":"Predicting and Understanding the Human Microbiome\u2019s Impact on Pharmacology","volume":"40","author":"Hitchings","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.medj.2024.03.020_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/science.aag2770","article-title":"Chemical transformation of xenobiotics by the human gut microbiota","volume":"356","author":"Koppel","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.medj.2024.03.020_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/03602532.2018.1497647","article-title":"Gut microbiota modulates drug pharmacokinetics","volume":"50","author":"Zhang","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.medj.2024.03.020_bib13","series-title":"Sex and Gender Differences in Pharmacology Handbook of Experimental Pharmacology","first-page":"411","article-title":"Sex Differences in the Drug Therapy for Oncologic Diseases","author":"Schmetzer","year":"2012"},{"key":"10.1016\/j.medj.2024.03.020_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1126\/science.aax7621","article-title":"Dosing time matters","volume":"365","author":"Ruben","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.medj.2024.03.020_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/17425250902800153","article-title":"Ethnic differences in drug metabolism and toxicity from chemotherapy","volume":"5","author":"Phan","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.medj.2024.03.020_bib16","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/FTD.0b013e3181b9b8c0","article-title":"Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer","volume":"31","author":"Beumer","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.medj.2024.03.020_bib17","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1515\/cclm-2012-0641","article-title":"Comparative evaluation of the My5-FU\u2122 immunoassay and LC-MS\/MS in monitoring the 5-fluorouracil plasma levels in cancer patients","volume":"51","author":"B\u00fcchel","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.medj.2024.03.020_bib18","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.medj.2024.03.020_bib19","first-page":"263","article-title":"Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study","volume":"11","author":"Capitain","year":"2012","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.medj.2024.03.020_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1109\/MCS.2017.2766314","article-title":"Individualized model predictive control for the artificial pancreas: In silico evaluation of closed-loop glucose control","volume":"38","author":"Messori","year":"2018","journal-title":"IEEE Control Syst. Mag."},{"key":"10.1016\/j.medj.2024.03.020_bib21","series-title":"FDA Authorizes First Interoperable, Automated Insulin Dosing Controller Designed to Allow More Choices for Patients Looking to Customize Their Individual Diabetes Management Device System","year":"2020"},{"key":"10.1016\/j.medj.2024.03.020_bib22","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","article-title":"Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes","volume":"381","author":"Brown","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.03.020_bib23","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.2337\/db11-0654","article-title":"Artificial Pancreas: Past, Present, Future","volume":"60","author":"Cobelli","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.medj.2024.03.020_bib24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tem.2019.04.008","article-title":"A Century of Diabetes Technology: Signals, Models, and Artificial Pancreas Control","volume":"30","author":"Kovatchev","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.medj.2024.03.020_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41551-017-0070","article-title":"Closed-loop control of circulating drug levels in live animals","volume":"1","author":"Mage","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.medj.2024.03.020_bib26","series-title":"Quantitative Chemical Analysis","author":"Harris","year":"2010"},{"key":"10.1016\/j.medj.2024.03.020_bib27","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1038\/s41598-021-82908-8","article-title":"Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS\/MS and clinical application in monitoring UFT\/LV combination therapy after hepatectomy","volume":"11","author":"Shiraiwa","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2024.03.020_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/acsptsci.8b00033","article-title":"High-Precision Control of Plasma Drug Levels Using Feedback-Controlled Dosing","volume":"1","author":"Arroyo-Curr\u00e1s","year":"2018","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.medj.2024.03.020_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchromb.2013.02.031","article-title":"A validated HPLC\u2013MS\/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: Application to a clinical pharmacokinetic study","volume":"926","author":"Furlong","year":"2013","journal-title":"J.\u00a0Chromatogr. B"},{"key":"10.1016\/j.medj.2024.03.020_bib30","doi-asserted-by":"crossref","first-page":"81880","DOI":"10.18632\/oncotarget.11980","article-title":"Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients","volume":"7","author":"Fang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.medj.2024.03.020_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1078-0432.CCR-19-1483","article-title":"Clinical Assessment of 5-Fluorouracil\/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype\u2013Guided Dosing","volume":"26","author":"Joshi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.03.020_bib32","article-title":"Making Fluorouracil \u201cSexy\u201d Again","author":"Boland","year":"2020","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.medj.2024.03.020_bib33","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bcp.13007","article-title":"Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers","volume":"82","author":"Jacobs","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.medj.2024.03.020_bib34","first-page":"197","article-title":"Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion","volume":"50","author":"Harris","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2024.03.020_bib35","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.medj.2024.03.020_bib36","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2217\/pgs.11.72","article-title":"Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity","volume":"12","author":"Amstutz","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.medj.2024.03.020_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil","volume":"16","author":"Diasio","year":"1989","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.medj.2024.03.020_bib38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1078155217732141","article-title":"Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature","volume":"25","author":"Zurayk","year":"2019","journal-title":"J.\u00a0Oncol. Pharm. Pract."},{"key":"10.1016\/j.medj.2024.03.020_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage","author":"Gamelin","year":"1999","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.03.020_bib40","first-page":"64","article-title":"Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother","volume":"16","author":"Thyss","year":"1986","journal-title":"Pharmacol."},{"key":"10.1016\/j.medj.2024.03.020_bib41","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/00001813-200310000-00003","article-title":"Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer","volume":"14","author":"Schmoll","year":"2003","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.medj.2024.03.020_bib42","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0026-895X(24)26498-1","article-title":"Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil in the presence of NADPH","volume":"57","author":"Nishiyama","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.medj.2024.03.020_bib43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00280-016-3063-1","article-title":"Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency","volume":"78","author":"Saif","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.medj.2024.03.020_bib44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/NUR.0000000000000198","article-title":"Vistogard (Uridine Triacetate): The First and Only Drug Approved for the Treatment of 5-Fluorouracil or Capecitabine Overdose: Implications for the Clinical Nurse Specialist","volume":"30","author":"O\u2019Malley","year":"2016","journal-title":"Clin. Nurse Spec."},{"key":"10.1016\/j.medj.2024.03.020_bib45","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ijc.2910410411","article-title":"Dose Versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU","volume":"41","author":"Milano","year":"1988","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.medj.2024.03.020_bib46","series-title":"Process Dynamics and Control","author":"Seborg","year":"2011"},{"key":"10.1016\/j.medj.2024.03.020_bib47","article-title":"Bioanalytical Method Validation Guidance for Industry","year":"2020","journal-title":"US Food Drug Adm"},{"key":"10.1016\/j.medj.2024.03.020_bib48","first-page":"1507","article-title":"Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"6","author":"Chen","year":"2013","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.medj.2024.03.020_bib49","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jnci\/86.21.1608","article-title":"Chronomodulated Versus Fixed-Infusion\u2014Rate Delivery of Ambulatory Chemotherapy With Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in Patients With Colorectal Cancer Metastases: a Randomized Multi-institutional Trial","volume":"86","author":"L\u00e9vi","year":"1994","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.medj.2024.03.020_bib50","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(97)03358-8","article-title":"Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy","volume":"350","author":"L\u00e9vi","year":"1997","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.medj.2024.03.020_bib51","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","article-title":"Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy","volume":"157","author":"Clarke","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.medj.2024.03.020_bib52","series-title":"2011 International Conference on Power Engineering, Energy and Electrical Drives","first-page":"1","article-title":"Real-time detection of oscillations in control loops","author":"Palma","year":"2011"},{"key":"10.1016\/j.medj.2024.03.020_bib53","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.2023.1792","article-title":"Cost-effectiveness Thresholds Used by Study Authors, 1990-2021","volume":"329","author":"Neumann","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2024.03.020_bib54","article-title":"Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England","volume":"29","author":"Cherla","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.medj.2024.03.020_bib55","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/mas.21614","article-title":"Miniaturization in Mass Spectrometry","volume":"39","author":"Mielczarek","year":"2020","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.medj.2024.03.020_bib56","unstructured":"Discrete-time PID Controller Implementation | ESI Group (2015). https:\/\/www.scilab.org\/discrete-time-pid-controller-implementation."},{"key":"10.1016\/j.medj.2024.03.020_bib57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1191\/0960327106ht628oa","article-title":"Cardiac lesions induced by 5-fluorouracil in the rabbit","volume":"25","author":"Tsibiribi","year":"2006","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.medj.2024.03.020_bib58","article-title":"The Appearance of Endothelium in Small Arteries After Treatment with 5-Fluorouracil. An Electron Microscopic Study of Late Effects in Rabbits","volume":"10","author":"Cwikiel","year":"1996","journal-title":"Scanning Microsc."},{"key":"10.1016\/j.medj.2024.03.020_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.medj.2024.03.020_bib60","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1538\/expanim.18-0028","article-title":"Measurements of body surface area and volume in laboratory rabbits (New Zealand White rabbits) using a computed tomography scanner","volume":"67","author":"Itoh","year":"2018","journal-title":"Exp. Anim."},{"key":"10.1016\/j.medj.2024.03.020_bib61","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.03.020_bib62","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2024.03.020_bib63","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1200\/JCO.2012.42.5355","article-title":"Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)","volume":"30","author":"Schmoll","year":"2012","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.medj.2024.03.020_bib64","unstructured":"Consumer Price Index: U.S. Bureau of Labor Statistics https:\/\/www.bls.gov\/cpi\/."},{"key":"10.1016\/j.medj.2024.03.020_bib65","volume":"67","author":"Arias","year":"2015"},{"key":"10.1016\/j.medj.2024.03.020_bib66","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","article-title":"Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)","volume":"27","author":"Yamazaki","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.medj.2024.03.020_bib67","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024001326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024001326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:00:09Z","timestamp":1762639209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024001326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2666634024001326"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.03.020","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Closed-loop automated drug infusion regulator: A clinically translatable, closed-loop drug delivery system for personalized drug dosing","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}